Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study
Epilepsia1999Vol. 40(7), pp. 965–972
Citations Over TimeTop 10% of 1999 papers
Michael J. McLean, Martha J. Morrell, L. James Willmore, Michael Privitera, Edward Faught, Gregory L. Holmes, Leslie Magnus‐Miller, Peter R Bernstein, Andrea Rose‐Legatt
Abstract
Gabapentin doses >1,800 mg/day were as well tolerated as doses < or =1,800 mg/day and were not associated with more adverse events.
Related Papers
- → A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine(2017)53 cited
- → Rapid Dose Escalation With Quetiapine(2005)31 cited
- → Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update(2004)39 cited
- → Gabapentin as Adjunctive Therapy for Partial Seizures(1999)12 cited
- → Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers(1998)2 cited